Increased levels of tPA antigen and tPA/PAI-1 complex in myotonic dystrophy

Journal of Internal Medicine

Volumn 249, Issue 6, 2001, Pages 503-510

  Johansson, A ^a   Boman, K ^a,b   Cederquist, K ^a   Forsberg, H ^c   Olsson, T ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b Skelleftea Hospital   (Sweden)

^c Boden Hospital   (Sweden)

Author keywords

Body composition; Dystrophia myotonica; Fibrinolysis; Lipids; Myotonic dystrophy

Indexed keywords

INSULIN; LIPID; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ANTIGEN DETECTION; ARTICLE; BODY COMPOSITION; BODY FAT; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; GENETIC ANALYSIS; HUMAN; IMPEDANCE; MAJOR CLINICAL STUDY; MALE; MYOTONIC DYSTROPHY; OUTPATIENT DEPARTMENT; PATHOGENESIS; PRIORITY JOURNAL;

ADULT; ANTIGENS; BODY COMPOSITION; CASE-CONTROL STUDIES; ELECTRIC IMPEDANCE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INSULIN; LIPIDS; MALE; MYOTONIC DYSTROPHY; PLASMINOGEN ACTIVATOR INHIBITOR 1; REGRESSION ANALYSIS; STATISTICS, NONPARAMETRIC; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0034840494     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.2001.00832.x     Document Type: Article

References (44)

1. Molecular basis of myotonic dystrophy: Expansion of a triplet (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member
2. Male hypogonadism in myotonic dystrophy is related to (CTG) n triplet mutation
3. Myotonic dystrophy: Correlation of clinical symptoms with the size of the CTG trinucleotide repeat
4. Cognitive impairment and (CTG) n expansion in myotonic dystrophy patients
5. Adrenocorticotropin hyperresponsiveness in myotonic dystrophy following oral fenfluramine administration
6. Adrenocorticotropin hyperresponse to the corticotropin-releasing hormone-mediated stimulus of naloxone in patients with myotonic dystrophy
7. Androgen response to hypothalamic-pituitary-adrenal stimulation with naloxone in women with myotonic dystrophy
8. Hypertriglyceridemia and lower LDL cholesterol concentration in relation to apolipoprotein E phenotypes in myotonic dystrophy
9. Tumor necrosis factor system activity is associated with insulin resistance and dyslipidemia in myotonic dystrophy
10. Insulin regulation of leptin synthesis and secretion in humans: The model of myotonic dystrophy
11. Adrenal steroid dysregulation in dystrophia myotonica
12. Abnormal cytokine and adrenocortical hormone regulation in myotonic dystrophy
13. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation
14. Basic and clinical aspects of fibrinolysis and thrombolysis
15. The relationship between plasminogen activator inhibitor-1 and insulin resistance in newly diagnosed type 2 diabetes mellitus
16. Production of plasminogen activator inhibitor 1 by human adipose tissue. Possible link between visceral fat accumulation and vascular disease
17. PAI-1 produced ex vivo human adipose tissue is relevant to PAI-1 blood levels
18. Regulation of fibrinolysis in the development of atherothrombosis: Role of adipose tissue
19. Predicitive value of fibrinolytic factors in coronary heart disease
20. Tissue plasminogen activator (tPA) antigen in plasma: Correlation with different tPA/inhibitor complexes
21. Tissue plasminogen activator (tPA), plasminogen activator inhibitor (PAI-1) and tPA/PAI-1 complex as risk factors for the development of a first stroke
22. Impedance: A valid method in assessment of body composition?
23. Why estimating impedance analysis should be used for estimating adiposity
24. The World Health Organization MONICA Project (monitoring of trends and determinants in cardiovascular diseases): A major international collaboration
25. Stroke around the Baltic Sea: Incidence, case fatality and population risk factors in Denmark, Finland, Sweden, and Lithuania
26. Adipose tissue as an endocrine and paracrine organ
27. Elaboration of type-1 plasminogen activator inhibitor from adipocytes. A potential pathogenetic link between obesity and cardiovascular disease
28. Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide
29. The metabolic syndrome - A neuroendocrine disorder?
30. The heart in myotonic disease
31. Pathology of the cardiac conduction system in myotonic dystrophy: A study of 12 cases
32. Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoproteins
33. Hypertriglyceridemia and regulation of fibrinolytic activity
34. Plasminogen activator inhibitor type-1 synthesis and mRNA expression in HepG2 cells are regulated by VLDL
35. Very-low-density lipoprotein response element in the promotor region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia
36. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study
37. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction
38. n expansions in various tissues from a myotonic dystrophy patient
39. The relationship of enzyme activity to feeding behavior in rats: Lipoprotein lipase as the metabolic gatekeeper
40. Fat cells
41. Potential role of TNFa and lipoprotein lipase as candidate genes for obesity